SLS: SELLAS Life Sciences Net earnings per share (EPS TTM)
SELLAS Life Sciences (SLS) ensures high-precision transport of biosamples, minimizing cargo spoilage and maintaining profitability. The TTM net income per share distribution demonstrates capital dynamics, where -0.21 reflects the latest metric value. The company develops vaccines based on GPS technology to combat relapses, although its survival depends on the results of Phase 3 trials amid critically low cash reserves.
SELLAS Life Sciences Group, Inc. - analytical breakdowns and key metrics (SLS)
- current quotes and average value forecast:
- market capitalization information:
- business book valuation details:
- debt and liquidity details:
Debt to Equity SELLAS Life Sciences|SLS - Long-Term Debt to Equity|Short-Term Debt to Equity SELLAS Life Sciences Group Inc.|SLS - Company Debts|Debts to Book Capitalization SELLAS Life Sciences Group|SLS - Company Long-Term Debts|Company Short-Term Debt SELLAS Life Sciences|Quick Liquidity Indicator sellaslifesciences.com
- earnings and multiples data:
SLS - Final Profit|Expected Profit SELLAS Life Sciences|SLS - Price to Earnings Ratio|Forward P/E Multiple SELLAS Life Sciences Group Inc.|SLS - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple SELLAS Life Sciences Group|SLS - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) SELLAS Life Sciences|SLS - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months sellaslifesciences.com|SLS - Earnings per share increase in current year|Net earnings per share growth forecast for next year SELLAS Life Sciences
Fundamental company valuation:sellaslifesciences.com (SLS)
For SELLAS Life Sciences (SLS), which integrates AI into oncology drug development, the rolling net income per share reflects the efficiency of capitalizing scientific achievements. The current value of -0.21 is calculated as the ratio of total annual net income to the number of common shares, allowing investors to filter out price noise and assess the real fundamental value of the business relative to industry peers.
Competitors of SELLAS Life Sciences (SLS)
ONC - Earnings per share for the last twelve months|Earnings per share for the trailing year HALO (halozyme.com)|RVMD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Ascentage Pharma Group International (AAPG)|Earnings per share for the last twelve months CG Oncology Corp|UroGen Pharma Corp (URGN) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) BCAX|PSNL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Erasca ERAS|Delcath Systems Inc - Earnings per share for the last twelve months|YMAB - Earnings per share for the last twelve months|AURA: Earnings per share for the last twelve months|CADL: Net earnings per share (EPS TTM)|accuray.com (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Actuate Therapeutics|Citius Oncology Inc. (CTOR) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months HURA (TuHURA Biosciences, Inc.)|TARA (Protara Tx) - Earnings per share for the trailing year|Earnings per share for the last twelve months Fate Therapeutics, Inc. FATE|Aadi Bioscience, Inc. - Earnings per share for the last twelve months|TScan - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Champions Oncology CSBR|XBIT: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months CVM (CEL-SCI)|OSTX (OS Therapies Incorporated) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months radiopharmtheranostics.com RADX|Net earnings per share for the last 12 months ARTV (Artiva Biotherapeutics, Inc.)|ANL (adlainortye.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Veru Pharma VERU|Net earnings per share for the last four quarters Tempest Therapeutics Corp (TPST)|Xilio - Net earnings per share (EPS TTM)|Renovaro Inc. (RENB) - Net earnings per share for the last 12 months|MURA: Net earnings per share (EPS TTM)|KAPA - Net earnings per share for the last four quarters|OKUR (OnKure Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CytoMed GDTC|Earnings per share for the last twelve months Curis, Inc. (CRIS)|apollomicsinc.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) THAR (Tharimmune)|ADVB - Net earnings per share for the last 12 months|Genprex, Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Calidi Biotherapeutics|Sunshine Biopharma, Inc. (SBFM) - Earnings per share for the last twelve months|XBIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Salarius Pharmaceuticals, Inc.|Purple Biotech Ltd (PPBT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months American Oncology Network (AONC)|Earnings per share for the last twelve months BGNE (BeiGene Ltd)|Earnings per share for the last twelve months Checkpoint Therapeutics CKPT|Net earnings per share for the last four quarters elevationoncology.com (ELEV)|iCAD Corp - Net earnings per share (EPS TTM)|Ikena Oncology, Inc. (IKNA) - Net earnings per share for the last 12 months|NTBL: Net earnings per share (EPS TTM)|Viracta Therapeutics, Inc. (VIRX) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months MorphoSys AG|Earnings per share for the last 12 months NAYA (nayabiosciences.com)|Net earnings per share (EPS TTM) AAPGV
